2020-06-18 sec-litreleases pdf 117 KB 2,317 chars

Qazi v. Mazs Mart Corp.

raw: It appears to the Securities and Exchange Commission (the “Commission”) that the

It appears to the Securities and Exchange Commission (the “Commission”) that the, No. 1:20-cv-11092 (June 18, 2020)

Caption
Qazi v. Mazs Mart Corp.
Exhibit of Gomes et al.;
Source PDF JSON
summary

The SEC suspended trading of Bioscience Neutraceuticals, Inc. securities from May 11 to May 22, 2020, due to concerns over inaccurate market information and suspicious stock promotions.

paragraph

The SEC issued an order to suspend trading in Bioscience Neutraceuticals, Inc. (DEVV) due to questions regarding business activity and suspicious email stock promotions. The Commission cited concerns over shareholder transparency and substantial selling of stock by a single account. No specific monetary penalties were detailed in the order, but the suspension was mandated to protect investors.

narrative

The Securities and Exchange Commission (SEC) issued an order to suspend trading in the securities of Bioscience Neutraceuticals, Inc. from May 11, 2020, through May 22, 2020. The suspension was prompted by concerns regarding the accuracy and adequacy of information in the marketplace, specifically noting an apparent lack of business activity. The SEC also identified suspicious email stock promotions from unknown sources that claimed potential price appreciation based solely on past performance. Additionally, the Commission raised questions regarding a lack of shareholder transparency and significant selling activity by a single account. The order was issued under Section 12(k) of the Securities Exchange Act of 1934 to protect the public interest and investors. The company's common stock was quoted on OTC Link under the symbol DEVV.

Enriched metadata

Scheme
financial-fraud (70%)
Case No.
1:20-cv-11092
Classified financial-fraud(confidence 70%). EDGAR detection: forms 10-K/10-Q/8-K/NT 10-K· recall 67% / precision 23%. detection rule →
Statutes
Section 12(k) of the Securities Exchange Act
Parties
QaziMazs Mart Corp.
Keywords
securitiessecurities exchangecommissionexchange commissionexchangebioscienceappears securitiescommission commissionsuspension tradingtrading securitiestradingcompanystockpublic interestinterest protection

Extracted insights

Entities 11
  • company bioscience neutraceuticals, inc.
  • company nevada corporation
  • person otc link
  • company Otc Markets Group Inc.
  • agency Securities and Exchange Commission
  • company securities of bioscience neutraceuticals, inc.
  • person single account
  • company trading in securities
  • company trading in the securities of bioscience neutraceuticals, inc.
  • person trading suspension
  • person unknown source
Triples 47
  • Securities and Exchange Commission suspended trading securities of Bioscience Neutraceuticals, Inc.
  • Bioscience Neutraceuticals, Inc. is Nevada corporation
  • Bioscience Neutraceuticals, Inc. located Chicago, Illinois
  • Bioscience Neutraceuticals, Inc. quoted on OTC Link
  • Bioscience Neutraceuticals, Inc. traded under symbol DEVV
  • Bioscience Neutraceuticals, Inc. had eight market makers
  • trading in securities suspended from 9:30 a.m. EDT on May 11, 2020
  • trading in securities suspended through 11:59 p.m. EDT on May 22, 2020
  • Commission issued order pursuant to Section 12(k) of the Securities Exchange Act of 1934
  • Vanessa A. Countryman is Secretary
  • Securities and Exchange Commission suspended trading in the securities of Bioscience Neutraceuticals, Inc.
  • Bioscience Neutraceuticals, Inc. is a Nevada corporation
  • Bioscience Neutraceuticals, Inc. has purported principal place of business located in Chicago, Illinois
  • Bioscience Neutraceuticals, Inc. is quoted on OTC Link under the symbol DEVV
  • trading suspension started 9:30 a.m. EDT on May 11, 2020
  • trading suspension ended 11:59 p.m. EDT on May 22, 2020
  • unknown source directed e-mail stock promotion to investors
  • single account engaged in substantial selling of Bioscience's stock
  • Bioscience Neutraceuticals, Inc. registered pursuant to Securities Exchange Act of 1934 Section 12(g)
  • Securities and Exchange Commission suspended trading securities of Bioscience Neutraceuticals, Inc. from May 11, 2020 to May 22, 2020
  • Bioscience Neutraceuticals, Inc. lacked business activity since at least March 20, 2020
  • unknown source sent email stock promotion claiming potential for continued appreciation in Bioscience’s stock based on past market performance
  • Bioscience Neutraceuticals, Inc. lacked shareholder transparency as of May 2020
  • single account sold substantial amount of stock of Bioscience Neutraceuticals, Inc. as of May 2020
  • Securities and Exchange Commission requires suspension of trading
  • Bioscience Neutraceuticals, Inc. has no business activity
  • unknown source sent email stock promotion to investors
  • Bioscience Neutraceuticals, Inc. lacks shareholder transparency
  • single account sold substantial amount of Bioscience stock
  • Bioscience Neutraceuticals, Inc. registered common stock under Exchange Act Section 12(g)
  • OTC Markets Group Inc. operates OTC Link (formerly Pink Sheets)
  • Securities and Exchange Commission orders suspension of trading from May 11, 2020, 9:30 a.m. EDT to May 22, 2020, 11:59 p.m. EDT
  • Bioscience Neutraceuticals, Inc. traded on OTC Link under symbol DEVV
  • Securities and Exchange Commission ordered suspension of trading in Bioscience Neutraceuticals, Inc. securities
  • Securities and Exchange Commission requires public interest and protection of investors
  • Bioscience Neutraceuticals, Inc. lacks business activity
  • Bioscience Neutraceuticals, Inc. has questions regarding accuracy and adequacy of information
  • Bioscience Neutraceuticals, Inc. has e-mail stock promotion from unknown source
  • Bioscience Neutraceuticals, Inc. has lack of shareholder transparency
  • Bioscience Neutraceuticals, Inc. has recent trading activity
  • Bioscience Neutraceuticals, Inc. is Nevada corporation
  • Bioscience Neutraceuticals, Inc. has principal place of business in Chicago, Illinois
  • Bioscience Neutraceuticals, Inc. has class of securities registered with Commission
  • Bioscience Neutraceuticals, Inc. is quoted on OTC Link
  • Bioscience Neutraceuticals, Inc. has eight market makers
  • Securities and Exchange Commission suspended trading in Bioscience Neutraceuticals, Inc. securities from May 11, 2020 to May 22, 2020
  • Vanessa A. Countryman is Secretary
PDF
It appears to the Securities and Exchange Commission (the “Commission”) that the · Source
Text layers
Extracted body text (2,317c) 

UNITED STATES OF AMERICA 
Be fore  the 
SECURITIES AND EXCHANGE COMMISSION 
 
May 11, 2020 
 
 
 
In the  Matte r of 
 
Bios cience Neutrace uticals, Inc. 
 
File  No. 500-1 
 
 
 
ORDER OF SUSPENSION OF 
TRADING 
 
 
 
  
 
It appears to  the Securities  and Exchange  Commission (the “Commission”) that the 
public  interest  and  the protection  of investors  require  a suspension  in  the trading  of  the securities 
of Bioscience  Neutraceuticals, Inc. (“Bioscience” or “the Company”) (CIK No. 0001555995) 
because of questions  regarding  the accuracy and  adequacy of information  in  the marketplace 
about  the Company  and  its  securities since  at least March 20, 2020.    
Those questions  relate to Bioscience’s apparent lack of business activity and an e-mail 
stock promotion  from an unknown  source directed  to investors  which  claimed a potential  for 
continued appreciation in the price of Bioscience’s stock based solely on its  past market 
performance.  There are also  questions  about (a) the lack of  shareholder  transparency,  and (b) the 
recent trading  activity  in  the securities  of Bioscience including  substantial  selling  of Bioscience’s 
stock by a single account.   
Bioscience is a Nevada corporation with its purported principal  place of business  located 
in Chicago, Illinois with  a class of securities  registered with  the Commission  pursuant  to 
Securities  Exchange  Act of 1934  ("Exchange  Act")  Section  12(g).  The Company’s common 
stock is  quoted  on OTC Link (previously “Pink  Sheets”),  operated by  OTC Markets Group  Inc., 

 2 
under  the symbol DEVV.  As of May 1, 2020, Bioscience’s common stock had eight market 
makers, and was eligible  for the “piggyback”  exception of Exchange Act Rule 15c2-11(f)(3).  
 The Commission  is of  the opinion  that  the public  interest  and the protection  of investors 
require  a suspension  of trading  in  the securities  of the above-listed Company. 
 THEREFORE,  IT IS ORDERED, pursuant  to Section  12(k)  of  the Securities  Exchange 
Act of 1934,  that trading  in  the securities  of the above-listed Company is  suspended for the 
period  from  9:30  a.m. EDT on May 11,  2020,  through  11:59  p.m.  EDT on May 22, 2020. 
By the Commission. 
 
 
Vanessa A. Countryman 
           Secretary
OCR text (2,255c · tika · 95% conf) 
UNITED STATES OF AMERICA 

Before the 

SECURITIES AND EXCHANGE COMMISSION 

 

May 11, 2020 

 

 

 

In the Matter of 

 

Bioscience Neutraceuticals, Inc. 

 

File No. 500-1 

 

 

 

ORDER OF SUSPENSION OF 

TRADING 

 

 

 

  

 
It appears to the Securities and Exchange Commission (the “Commission”) that the 

public interest and the protection of investors require a suspension in the trading of the securities 

of Bioscience Neutraceuticals, Inc. (“Bioscience” or “the Company”) (CIK No. 0001555995) 

because of questions regarding the accuracy and adequacy of information in the marketplace 

about the Company and its securities since at least March 20, 2020.   

Those questions relate to Bioscience’s apparent lack of business activity and an e-mail 

stock promotion from an unknown source directed to investors which claimed a potential for 

continued appreciation in the price of Bioscience’s stock based solely on its past market 

performance.  There are also questions about (a) the lack of shareholder transparency, and (b) the 

recent trading activity in the securities of Bioscience including substantial selling of Bioscience’s 

stock by a single account.   

Bioscience is a Nevada corporation with its purported principal place of business located 

in Chicago, Illinois with a class of securities registered with the Commission pursuant to 

Securities Exchange Act of 1934 ("Exchange Act") Section 12(g).  The Company’s common 

stock is quoted on OTC Link (previously “Pink Sheets”), operated by OTC Markets Group Inc., 



 2 

under the symbol DEVV.  As of May 1, 2020, Bioscience’s common stock had eight market 

makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).  

 The Commission is of the opinion that the public interest and the protection of investors 

require a suspension of trading in the securities of the above-listed Company. 

 THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange 

Act of 1934, that trading in the securities of the above-listed Company is suspended for the 

period from 9:30 a.m. EDT on May 11, 2020, through 11:59 p.m. EDT on May 22, 2020. 

By the Commission. 

 
 

Vanessa A. Countryman 
           Secretary

Related documents (6)